See more : Sinofibers Technology Co.,Ltd. (300777.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Celyad Oncology SA (CYAD.BR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Celyad Oncology SA, a leading company in the Biotechnology industry within the Healthcare sector.
- Telecomunicações Brasileiras S.A. – Telebras (TELB4.SA) Income Statement Analysis – Financial Results
- TNR Gold Corp. (TRRXF) Income Statement Analysis – Financial Results
- First Horizon Corporation (FHN-PF) Income Statement Analysis – Financial Results
- NextPlat Corp (NXPLW) Income Statement Analysis – Financial Results
- 361 Degrees International Limited (1361.HK) Income Statement Analysis – Financial Results
Celyad Oncology SA (CYAD.BR)
About Celyad Oncology SA
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 102.00K | 0.00 | 0.00 | 5.00K | 6.00K | 3.12M | 3.54M | 8.52M | 3.00K | 146.00K | 0.00 | 54.00K | 26.93K |
| Cost of Revenue | 69.00K | 1.44M | 1.52M | 0.00 | 0.00 | 0.00 | 515.00K | 53.00K | 6.38M | 115.00K | 2.42M | 6.68M | 5.80M |
| Gross Profit | 33.00K | -1.44M | -1.52M | 5.00K | 6.00K | 3.12M | 3.03M | 8.47M | -6.38M | 31.00K | -2.42M | -6.63M | -5.77M |
| Gross Profit Ratio | 32.35% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 85.45% | 99.38% | -212,633.33% | 21.23% | 0.00% | -12,276.54% | -21,427.74% |
| Research & Development | 4.67M | 18.93M | 20.77M | 21.59M | 25.23M | 23.58M | 22.91M | 27.68M | 5.90M | 15.87M | 2.16M | 0.00 | 0.00 |
| General & Administrative | 5.71M | 10.34M | 9.67M | 9.00M | 8.73M | 10.39M | 9.31M | 9.74M | 7.23M | 5.02M | 2.99M | 3.71M | 2.84M |
| Selling & Marketing | 215.00K | 239.00K | 434.00K | 454.00K | 607.00K | 676.00K | 761.00K | 728.00K | 891.00K | 394.00K | 206.19K | 0.00 | 0.00 |
| SG&A | 6.25M | 10.34M | 9.67M | 9.00M | 8.73M | 10.39M | 9.31M | 9.74M | 7.23M | 5.02M | 2.99M | 3.71M | 2.84M |
| Other Expenses | -2.43M | -9.00M | -3.53M | -4.34M | -4.58M | 7.32M | -23.79M | -2.52M | -222.00K | -963.00K | -1.02M | -2.84K | -270.21 |
| Operating Expenses | 8.49M | 20.26M | 26.91M | 26.24M | 29.38M | 41.29M | 29.63M | 34.08M | 29.68M | 19.92M | 11.08M | -5.19M | 3.31M |
| Cost & Expenses | 8.56M | 20.26M | 26.91M | 26.24M | 29.38M | 41.29M | 30.14M | 34.13M | 29.68M | 20.03M | 11.08M | 1.49M | 9.11M |
| Interest Income | 30.00K | 12.00K | 27.00K | 51.00K | 92.00K | 804.00K | 933.00K | 2.20M | 542.00K | 277.00K | 47.53K | 6.20K | -18.24K |
| Interest Expense | 84.00K | 197.00K | 255.00K | 297.00K | 343.00K | 62.00K | 4.45M | 207.00K | 236.00K | 22.00K | 425.42K | 627.45K | 33.30K |
| Depreciation & Amortization | 794.00K | 1.44M | 1.52M | 1.83M | 1.79M | 1.11M | 1.71M | 1.52M | 1.03M | 870.00K | 886.02K | 893.81K | 2.72M |
| EBITDA | -7.76M | -39.70M | -25.41M | -15.73M | -27.45M | -36.56M | -55.70M | -21.99M | -28.07M | -15.32M | -12.07M | -12.00M | -6.36M |
| EBITDA Ratio | -7,610.78% | 0.00% | 0.00% | -483,840.00% | -457,500.00% | -1,199.52% | -470.76% | -256.82% | -928,166.67% | -12,358.90% | 0.00% | 814.96% | -23,621.68% |
| Operating Income | -8.46M | -40.86M | -26.39M | -26.24M | -29.37M | -38.17M | -52.88M | -25.61M | -29.67M | -16.44M | -11.97M | -1.44M | -9.08M |
| Operating Income Ratio | -8,291.18% | 0.00% | 0.00% | -524,780.00% | -489,550.00% | -1,225.36% | -1,493.67% | -300.47% | -989,066.67% | -11,258.22% | 0.00% | -2,668.36% | -33,724.14% |
| Total Other Income/Expenses | -54.00K | -13.00K | -111.00K | -217.00K | 239.00K | 433.00K | -3.52M | 2.00M | 558.00K | -16.00K | -1.54M | -622.51K | -51.81K |
| Income Before Tax | -8.51M | -40.87M | -26.50M | -17.20M | -28.64M | -37.43M | -56.40M | -23.61M | -29.11M | -16.45M | -12.35M | -2.15M | -9.13M |
| Income Before Tax Ratio | -8,344.12% | 0.00% | 0.00% | -344,080.00% | -477,333.33% | -1,201.51% | -1,593.11% | -277.04% | -970,466.67% | -11,269.18% | 0.00% | -3,986.20% | -33,916.51% |
| Income Tax Expense | -191.00K | 65.00K | 10.00K | 297.00K | -8.00K | -1.11M | -1.00K | -6.00K | -55.00K | -2.48M | -360.00 | 1.70M | 51.81K |
| Net Income | -8.45M | -40.94M | -26.51M | -17.50M | -28.63M | -36.31M | -56.40M | -23.61M | -29.11M | -16.45M | -12.35M | -2.15M | -9.13M |
| Net Income Ratio | -8,282.35% | 0.00% | 0.00% | -350,020.00% | -477,200.00% | -1,165.75% | -1,593.08% | -276.97% | -970,466.67% | -11,269.18% | 0.00% | -3,986.20% | -33,916.51% |
| EPS | -0.33 | -1.81 | -1.70 | -1.26 | -2.29 | -3.26 | -5.86 | -2.53 | -3.43 | -2.44 | -3.01 | -0.53 | -1.44 |
| EPS Diluted | -0.33 | -1.81 | -1.70 | -1.26 | -2.29 | -3.26 | -5.86 | -2.53 | -3.43 | -2.44 | -3.01 | -0.53 | -1.44 |
| Weighted Avg Shares Out | 25.72M | 22.59M | 15.60M | 13.94M | 12.52M | 11.14M | 9.62M | 9.31M | 8.48M | 6.75M | 4.10M | 4.10M | 6.33M |
| Weighted Avg Shares Out (Dil) | 25.72M | 22.59M | 15.60M | 13.94M | 12.52M | 11.14M | 9.62M | 9.33M | 8.49M | 6.75M | 4.10M | 4.10M | 6.33M |
Source: https://incomestatements.info
Category: Stock Reports